Clinical Trials Logo

Community-Acquired Pneumonia clinical trials

View clinical trials related to Community-Acquired Pneumonia.

Filter by:

NCT ID: NCT06295120 Recruiting - Clinical trials for Community-acquired Pneumonia

The Optimal Antibiotic Treatment Duration for Community-acquired Pneumonia in Adults Diagnosed in General Practice in Denmark (CAP-D)

CAP-D
Start date: November 13, 2023
Phase: Phase 4
Study type: Interventional

The aim of this randomised controlled trial is to identify the optimal treatment duration with phenoxymethylpenicillin for community-acquired pneumonia diagnosed in general practice. Eligible participants are adults (≥18 years) presenting in general practice with symptoms of an acute LRTI (i.e., acute illness (≤ 21 days) usually with cough and minimum one other symptom such as dyspnea, sputum production, wheezing, chest discomfort or fever) in whom the GP finds it relevant to treat with antibiotics. Consenting patients who meet all the eligibility criteria will be randomised (1:1:1:1:1) to either three, four, five, six or seven days of treatment with phenoxymethylpenicillin 1.2 MIE four times daily.

NCT ID: NCT06294600 Recruiting - Clinical trials for Community-acquired Pneumonia

Clarithromycin Treatment to Prevent Sepsis Progression in CAP (REACT)

REACT
Start date: February 12, 2024
Phase: Phase 3
Study type: Interventional

The primary objective of the REACT randomized clinical trial (RCT) is to optimize the clinical benefit from adjunctive clarithromycin treatment shown in the ACCESS trial and to provide evidence for the clinical benefit of early start of adjunctive oral clarithromycin guided by suPAR to prevent the progression into sepsis in patients with community-acquired pneumonia (CAP) at risk. This can be achieved by endpoints incorporating clinical benefit with the effect of treatment on the improvement of the immune dysregulation of CAP. The secondary objectives of REACT are to investigate the impact of early adjunctive treatment with clarithromycin on the resolution of CAP at the test-of-cure (TOC) visit.

NCT ID: NCT06291012 Not yet recruiting - Clinical trials for Community-acquired Pneumonia

Stopping Pneumonia Antibiotherapy Regimen Early

SPARE
Start date: September 1, 2024
Phase: Phase 4
Study type: Interventional

The hypothesis for this trial is that an antibiotic strategy for the management of non-severe community-acquired alveolar pneumonia in children aged 3 to 59 months, including amoxicillin 80-100 mg/kg/day for at least 3 days in case of rapid response and 5 days in case of delayed response, would not be inferior to current French recommendations (antibiotic therapy for 5 days in case of rapid response and 7 days in case of delayed response) in terms of treatment of failure rate at 7 days.

NCT ID: NCT06279624 Not yet recruiting - Clinical trials for Community-acquired Pneumonia

Effectiveness of the PCV13 in Older Thai Adults

Start date: February 2024
Phase:
Study type: Observational

This is the matched 1:2 case-control study, prospectively collect case and control who are diagnosed with pneumococcal or non-pneumococcal community acquired pneumonia (CAP), accordingly from November 2023 through October 2024. The investigators define a CASE as a person aged ≥60 years due to pneumococcal confirmed CAP either in-patients or out-patients by doctor in charge. While a CONTROL is defined as a person aged ≥60 years due to non-pneumococcal confirmed CAP either in-patients or out-patients by doctor in charge. The goal of this observational study is to evaluate the effectiveness of the 13-valent pneumococcal conjugate vaccine (PCV13) in pneumococcal CAP in Thai adults aged ≥ 60 years with or without any medical conditions. The main questions it aims to answer is: • What are the effectiveness of PCV13 for preventing all typed, vaccine typed, or non-vaccine typed of pneumococcal CAP among Thai older adults? The investigators retrospectively collect cases and control who are diagnosed with CAP accordingly from January 2012 through October 2023. The investigators define case and control the same as prospective method, but all data were retrieved from archive database. -The investigators select a 1:2 matched control with criteria as follows; 10-year-interval of age, ward (the same patient care such as out or in-patient, or admitted in the same level ward). Participants will be - collated from hospital database regarding their CAP illnesses by pneumococcal and non-pneumococcal pneumonia condition. - explored their vaccine status by either vaccine book checking or hospital database. Researcher will compare the effectiveness of PCV13 to prevent all typed, vaccine typed and non-vaccine typed pneumococcal pneumonia.

NCT ID: NCT06272994 Not yet recruiting - Clinical trials for Community-acquired Pneumonia

Swab Testing to Optimize Pneumonia Treatment With Empiric Vancomycin

STOP-Vanc
Start date: December 1, 2024
Phase: N/A
Study type: Interventional

This is a single center, pragmatic, randomized clinical trial (pRCT) examining whether reporting the results of a negative rapid PCR back to the provider via a pager alert results in decreased vancomycin utilization for critically ill adults with community-acquired pneumonia when compared with usual care.

NCT ID: NCT06263881 Recruiting - Pneumonia Clinical Trials

Clinical Trial of the Efficacy and Safety of Raphamin in Combined Treatment of Community-acquired Pneumonia

Start date: December 1, 2023
Phase: Phase 3
Study type: Interventional

Multicenter double-blind placebo-controlled randomized in parallel groups clinical trial.

NCT ID: NCT06259110 Not yet recruiting - Clinical trials for Community-acquired Pneumonia

Community-Acquired Pneumonia Diagnosis Through Integrating Novel Microbiological Techniques.

Start date: February 25, 2024
Phase:
Study type: Observational

To evaluate novel microbiological techniques for enhanced Pathogen Identification, assess the speed and efficiency of the integrated approach in providing timely diagnostic results, aiming to reduce the turnaround time for CAP diagnosis and subsequently improve patient outcomes and evaluate the clinical impact of enhanced precision in CAP diagnosis on treatment decisions, including the potential for targeted and more effective antimicrobial therapy based on accurate pathogen identification.

NCT ID: NCT06229288 Not yet recruiting - Clinical trials for Community-acquired Pneumonia

Amoxicillin Alone Versus Amoxicillin/Clavulanate for Community-acquired Pneumonia in Patients Aged 65 Years or Older, and Hospitalized in a Non-intensive Care Unit Ward

CAPTAIN
Start date: March 15, 2024
Phase: Phase 3
Study type: Interventional

Reduce inappropriate antibiotic use is a priority of public health agencies. Community-acquired pneumonia (CAP) is one of the most important indications for antibiotic prescriptions. In the majority of the studies of CAP, there is a large proportion of cases with no pathogen identified. Thus, the choice of the empirical antibiotic depends on the most likely pathogen, individual risk factors, comorbidities, and allergies. Patients aged 65 years or older are often treated with amoxicillin/clavulanate or with another broad-spectrum antibiotic (third-generation cephalosporins, antipneumococcal fluoroquinolone). However, broad-spectrum antibiotic prescription in CAP is debated and concerns exist about side-effects and selective pressure for resistance. Due to lack of head-to-head antibiotic comparisons, a recent Cochrane review concluded that current evidence from Randomized Clinical Trials (RCTs) is insufficient to make evidence-based recommendations for the choice for antibiotic to be used, highlighting an important evidence gap.

NCT ID: NCT06220019 Not yet recruiting - Clinical trials for Community Acquired Pneumonia

TCM Syndrome Differentiation and Treatment Reduce the Rate of CAP Rehospitalization

Start date: January 2024
Phase:
Study type: Observational

The purpose of this study is to evaluate the clinical efficacy and safety of dialectical treatment in the patients with CAP after discharge in a prospective cohort study: one is the Traditional Chinese Medicine (TCM) cohort, which has been evaluated and has certain effects; The other is a non traditional Chinese medicine queue.

NCT ID: NCT06210282 Recruiting - Clinical trials for Community Acquired Pneumonia

The Effect of Focused Lung Ultrasonography on Antibiotic Prescribing in General Practice

PLUS-FLUS
Start date: November 3, 2023
Phase: N/A
Study type: Interventional

The goal of this randomised controlled trial is to determine if adults presenting with symptoms of an acute lower respiratory tract infection in general practice where the general practitioner suspects CAP, who have FLUS performed as an addition to usual care, have antibiotics prescribed less frequent compared to those given usual care only.